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The role of magnetic resonance imaging  
in the diagnosis of breast cancer
Barbara Bobek-Billewicz1, Marek K. Jurkowski2, 3
MR mammography is a highly sensitive (> 98%) and slightly lower specificity (> 80%) method of detecting breast 
cancer. The sensitivity of MR mammography in detecting low or medium grade DCIS is lower than in detecting inva-
sive carcinomas and high grade DCIS. Achieving the high efficacy of MR mammography is only possible with a very 
good quality MR examination; this however is not always easy to accomplish. 
According to EUSOBI 2015 recommendations, the indications for breast MRI are: screening women with a high risk 
of breast cancer; preoperative staging of newly diagnosed breast cancer; evaluating the response to neoadjuvant 
chemotherapy; occult primary breast carcinoma (searching for breast cancer in patients with metastases and nega-
tive mammography and breast ultrasound); suspected local recurrence whenever needle biopsy proves impossible; 
assessing breast implants; further characterisation of equivocal lesions found by mammography/breast ultrasound, 
whenever needle biopsy proves impossible.
The introduction of Digital Breast Tomosynthesis (DBT) and contrast-enhanced spectral mammography (CESM) into 
daily clinical practice in the recent years has created the need to re-analyse the indications for MR mammography 
and to develop a new breast cancer diagnostic imaging algorithm.
NOWOTWORY J Oncol 2017; 67, 3: 185–192
Key words: breast cancer, magnetic resonance imaging, breast MRI, MR mammography, occult breast cancer
Introduction
There are three main imaging modalities used in the 
diagnosis of breast cancer:
1. X-ray mammography (MMG, 2D MMG). Nowadays 
ever more frequently performed digitally, however analogue 
or CR (computed radiography) mammography systems are 
still in use. Digital mammography enables further diagnostic 
methods such as DBT (digital breast tomosynthesis) and 
CESM (contrast-enhanced spectral mammography).
A. DBT eliminates the tissue overlap and allows to assess 
the breast in 1 mm slices. It is most commonly under-
taken instead of targetted spot compression views, 
not only allowing further investigation of uncertain or 
suspicious lesions by the means of 2D MMG, but addi-
tionally allowing the assessment of the entire breast. 
DBT clarifies the nature of most opacities/asymmetric 
densities observed in single projections and improves 
the sensitivity and specificity of mammography. In wo-
men with diagnosed breast cancer, DBT can be used for 
the assessment of multifocality / multicentricity. It holds 
promise for a screening method [1]. 
B. (Dual energy) contrast-enhanced spectral mammogra-
phy (CESM) is the earliest of the imaging methods used 
in diagnosing breast cancer, it is in use since 2011. It is 
performed after an intravenous injection of an iodine-
-based contrast agent. Similarly to MR mammography, 
the contrast enhancement depends on the vasculari-
sation of the lesion [2, 3]. The main indication for CESM 
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appear to be equivocal lesions found in mammography 
or breast ultrasound in patients diagnosed with breast 
cancer, where additional cancer foci need to be confir-
med/excluded (Fig. 1) [4]. 
2. Ultrasonography. Usually this is classical hand held 
ultrasound performed by a doctor, which can be supplemented 
by the assessment of vascularization using the colour Doppler 
option and by the elastrography. Ultrasound can be performed 
following an intravenous administration of a contrast agent. 
A special type of breast ultrasound is the ABUS (Automated Bre-
ast Ultrasound), which also allows coronal sections of the breast 
to be investigated which would be impossible by classical hand 
held ultrasound examinations; one of its main advantages is 
repeatability. The examination is performed by a technician/ 
/radiographer but analysed and reported by a radiologist. 
3. MR mammography is a highly sensitivity method 
in the diagnosis of breast cancer (> 98%) with a slightly 
lower specificity (> 80%), and outcomes are influenced by 
the quality of the examination — this is not always easy to 
achieve. The sensitivity of MRI in detecting low and inter-
mediate grade DCIS is lower than for the high grade DCIS 
and invasive cancer [5].
MR mammography
In order to obtain high quality breast MR, it is necessary 
to keep to the principles and standards described, inter alia, 
by the EUSOMA recommendations [6, 7].
A.  In premenopausal women, the breast MRI should be 
performed between the 7th and 14th day of the monthly 
cycle when the contrast enhancement of the glandular 
breast tissue is poor and consequently the pathological 
contrast enhancement of the tumour is more conspi-
cuous and, at the same time, yields less false positive 
results. If required, this examination can be performed 
in the third week of the cycle, bearing in mind that the 
outcome may not be optimal.
B.  The MR scanner used for breast MRI examinations should 
have the minimum magnetic field strength of 1.5 T; a de-
dicated surface coil for breast imaging should be used.
C.  The following sequences should at the very least be 
obtained: T1-weighted and T2-weighted images, dy-
namic study following intravenous administration of 
a Gd-based contrast agent, performed in a T1-weighted 
high spatial resolution sequence with a suppression of 
the fatty tissue signal. The dynamic study should consist 
of 5 repetitions, with each repetition lasting a maximum 
of 120 seconds (in the currently used systems this should 
not exceed 90 s); the entire study time being approxi-
mately 20–30 min.
D.  Diffusion weighted MR imaging (DWI/ADC) does not 
require administering any contrast agent and improve 
the specificity of the study. 
E. The high-dynamic resolution sequence performed in 
the first 60–90 seconds after intravenous administration 
Figure 1. 45-year-old woman. Left breast: invasive carcinoma NST, G2, NG2. A. Spectral mammography in CC projection; both images performed 
after i.v. administartion of a contrast agent. On the left, low energy acquisition like standard mammography. On the right, subtracted image; dual 
energy mammography with contrast enhancement. B. Spectral mammography in MLO projection; both images performed after i.v. administartion 
of a contrast agent. On the left, low energy acquisition like standard mammography. On the right, subtracted image; dual energy mammography 
with contrast enhancement. Contrast-enhancing tumour in the upper outer quadrant of the left breast. Subtracted images showing only contrast- 
-enhancing lesions allow for an improved evaluation of the size and number of cancerous lesions
A B
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of Gd-based contrast agent does not prolong the test 
time, but it improves the specificity [8].
F. It is vital that the patient is physically placed in such 
a way that the entire area of interest is covered, ensu-
ring that the patient is comfortable enough to remain 
motionless for the duration of the test, particularly for 
the dynamic sequence. Whilst modern MR systems are 
equipped in motion correction software, this is only 
possible in certain circumstances. 
G. Studies aimed for the evaluation of the implant integrity 
can be performed without administering an intravenous 
contrast agent. In cases of silicone implants, dedicated 
sequences are required for the evaluation of the silicone.
Indications for MR mammography 
These were first comprehensively described in 2010 by 
the EUSOMA recommendations [6]. From the very begin-
ning, this document has raised controversy and particularly 
heated discussions concerning the role of the breast MRI 
in pre-treatment staging of the disease and diagnosing 
recurrent cancer.
The EUSOBI recommendations presented in 2015 [7] 
greatly extend the indications for breast MR and include:
A. Screening women with a high risk of breast cancer.
B. Preoperative staging of newly diagnosed breast cancer, 
Figure 2. 
C. Evaluating effects of neoadjuvant chemotherapy.
D. Occult primary breast carcinoma (Fig. 2), (searching for 
breast cancer in patients with metastases and negative 
mammography and ultrasound).
E. Suspected local recurrence whenever needle biopsy 
proves impossible.
F. Evaluating women with breast implants.
G. Further characterisation of equivocal lesions found by 
mammography / ultrasound, whenever needle biopsy 
proves impossible.
Indications for breast MRI, that do not raise any signifi-
cant doubts include:
A. Screening of women running a high risk of breast cancer 
(BRCA1 or BRCA2 mutation carriers and their relatives), 
women with other genetic syndromes with increased 
risk of breast cancer such as the Li-Fraumeni syndrome 
and Cowden syndrome along with those undergoing 
chest radiotherapy aged between 10 and 30 years and 
those having a risk of breast cancer > 20%.
Women with cancer in one breast have an increased risk 
of developing a second cancer, which may be an indication 
for performing pre-treatment MR breasts imaging as well 
as in the post treatment follow up.
B. Assessing the response to neoadjuvant chemotherapy 
in women with breast cancer.
C. Occult breast cancer.
D. Evaluating implants.
Ad A. MR Mammography is a recognised screening 
method for women with a high risk of breast cancer [5–7, 9]. 
Nowadays it is unquestionable that MR imaging should be 
used for screening women running a high risk of breast 
cancer; the only debatable point being how this should 
be performed.
The recommended age for starting MR screening is un-
der discussion, (according to EUSOMA this should be no later 
than at 30 years), and so are the intervals between screening, 
(of no longer than 1 year), and the actual screening metho-
dology. Several years ago Christiane Kuhl  [10] proposed 
a shortened MR mammogram protocol as a screening test 
using a 3 minute acquisition time, comprising performing 
two successive 3D T1-weighted sequences pre- and post 
intravenous administration of Gd-based contrast agent. 
In addition, a 1–2 minute localisation sequence will be ne-
eded thus extending the total time to around 5 minutes. 
The test duration is comparable to that of classical X-ray 
mammography, but is shorter than sonomammography 
of both breasts. The authors concluded that such exami-
nation, with a 3 minute MR examination and 3-second MIP 
reconstruction assessment by an expert radiologist being 
capable of excluding cancer with a NPV of 99.8%. With the 
time needed to evaluate the entire shortened protocol MRI 
breasts of less than 30 sec, the diagnostic efficacy achieved 
is comparable to that of the full protocol and additional 
18.2 cancers in 1000 were detected [10].
Ad B. Both dynamic imaging (following the administra-
tion of an intravenous Gd-based contrast agent) and diffu-
sion-weighted MR imaging are used to assess the response 
to neoadjuvant chemotherapy (NAC). Even the weak contrast 
enhancement at the site of the primary tumour post-NAC 
should be considered as representing residual tumours. Wo-
odhams et al. obtained 96% efficacy of DWI/ADC (Diffusion-
-weighted Imaging/Apparent diffusion coefficient) and 89% 
DCE (Dynamic contrast-enhanced) efficacy in diagnosing re-
sidual tumours [11]. Employing the DWI/ADCs for evaluating 
residual lesions may be particularly useful in women who, 
(for example because of renal failure), cannot undergo an 
intravenous administration of a paramagnetic contrast agent.
Ad C. Occult breast cancer accounts for less than 1% 
of breast cancers; in such cases MR imaging is indicated if 
X-ray mammography and breast ultrasound prove negative. 
Detecting breast cancer allows breast conserving surgery to 
be adopted instead of mastectomy. For women with breast 
cancer metastases, there is no clear answer as to whether 
classical mammography or the DBT and, if appropriate, spec-
tral mammography, should be used before the MRI breasts. 
For most cases this probably depends on local clinical condi-
tions and the availability of diagnostic imaging methods. As 
previously mentioned, MR sensitivity for detecting DCIS with 
low and intermediate grade malignancy is lower than for 
detecting high-grades of invasive cancer and DCIS (Fig. 3).
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Figure 2. 30-year-old woman. Left breast: invasive carcinoma NST, G2, NG2. A. Mammography — CC projection. B. Mammography — MLO 
projection; an asymmetric density in the left breast, close to the chest wall, up to about 18 mm in the largest diameter. C. Breast MRI;  
MIP reconstruction (maximum intensity projection). An irregular shaped infiltration in the upper outer quadrant and bordering the upper 
quadrants of the left breast, with the maximum diameter of 66 × 46 × 52 mm
A
B
C
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Figure 3. 52-year-old woman. Metastases to the right axillary lymph nodes, to the mediastinum and bones. Mammography shows scattered 
microcalcifications, not forming clusters; DBT did not reveal any suspicious lesions. A. Mammography — CC projection. B. Mammography — MLO 
projection. C. Breast MRI; MIP reconstruction. An area of abnormal ductal enhancement in the upper outer quadrant of the right breast, measuring 
up to 75 × 45 × 70 mm in diameter. HP: invasive NST, G3 carcinoma
A
B
C
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Ad D.  MR imaging is the gold standard in evaluating 
the integrity of silicone implants. An MRI scan undertaken 
solely for the purpose of assessing the implant integrity 
is performed without administering intravenous contrast 
agents and is based on the assessment of the sequences 
dedicated to silicone evaluation. If the purpose is to also 
detect neoplastic lesions, then complete MR imaging with 
dynamic imaging after intravenous administration of a pa-
ramagnetic contrast agent should be performed as well as 
the sequences dedicated to the evaluation of the silicone. 
It is of key importance that implants do not reduce MR sen-
sitivity for detecting breast cancer, including recurrences, 
and therefore breast MRI appears to be the gold imaging 
standard in such patients.
The greatest debate concerns the indications for breast 
MRI prior to starting treatment, local recurrence suspicion 
and assessing equivocal lesions by the means of mammo-
graphy and ultrasonography (BIRADS 3, BIRADS 4A and 
BIRADS 4B). MR imaging in patients with diagnosed breast 
cancer generally aims to help select the best treatment 
option. The first proposed EUSOMA [6] indications recom-
mended that MR imaging should be used prior to treatment 
in patients with newly diagnosed breast cancer in the fol-
lowing situations:
 — invasive lobular carcinoma;
 — high risk of breast cancer;
 — greater than 1cm difference in tumour size when asses-
sed by mammography and ultrasound;
 — before PBI (Partial Breast Irradiation).
At present, particularly in the clinical practice, the predo-
minant view is that the MR mammography should be perfor-
med to assess the local disease extent prior to starting the 
treatment, especially in women with a dense and glandular 
breast structure. This allows the detection of the additional 
cancer foci both in the breast with the known cancer and 
the contralateral breast (multi-focality and multi-centicity), 
as well as to better determine the size of the cancer and 
thus improve the treatment planning, including the surgical 
intervention [12]. Paker et al. states that 41% of surgeons, 
responding to a 2010 questionnaire issued to members of 
the American Society of Breast Surgeons, routinely under-
took MR mammography for patients with newly diagnosed 
breast cancer [13].
Undoubtedly MR mammography can detect cancer 
foci invisible to X-ray mammography and ultrasonogra-
phy. A meta-analysis by Brennan et al. on 3252 women with 
unilateral breast cancer found that 131 breast cancer lesions 
in the contralateral breast were only conspicuousin breast 
MRI. DCIS comprised 35% of these lesions [14].
Based on an MR analysis, in women with newly diagno-
sed breast cancer, Freitas et al. found a high 95% efficacy 
of the study, with the NPV of 98% when excluding occult 
cancer [15].
A discussion has been raised on the significance for 
treatment outcome of detecting the cancers invisible by 
some diagnostic methods and whether all the visible cancer 
foci should be surgically removed if breast radiotherapy and 
adjuvant systemic therapy are to be used [5, 16]. Most assu-
redly, lesions detected by MR mammography as BIRADS 4 or 
BIRADS 5 must be microscopically verified before deciding 
to alter the methods or the scope of treatment. Because 
most of these lesions are only visible in MR mammography, 
biopsies must be performed under MR guidance.
MR mammography performed prior to surgical treat-
ment results in increased mastectomy rates [17]. Studies on 
the effect of preoperative MR mammography on reducing 
the reoperation rate, when margins prove positive, are in-
consistent [18–20] and so are the studies on the effect of 
preoperative MR imaging on local recurrence rates [21, 22].
MR imaging is an effective method for diagnosing local 
recurrence after the breast conserving treatment. According 
to the classical indications, it should be performed when the 
X-ray mammography or breast ultrasound is inconclusive 
and when a biopsy cannot be undertaken. In clinical prac-
tice, MR mammography is often performed as a primary 
screening test after breast conserving treatment in young 
women with dense glandular breast. It appears possible 
that in some cases, MR mammography can be replaced by 
spectral mammography after an intravenous administration 
of a contrast agent.
Further characterisation of equivocal lesions, seen in 
X-ray mammography and breast ultrasound, was not ta-
ken into account in the initially proposed indications for 
performing MR mammography, however in current clinical 
practice this now usually constitutes the most frequent 
indication for this study. It should be remembered that MR 
mammography is much more effective in the assessment 
of masses, asymmetric densities or architectural distortions 
rather than in characterising the microcalcification. Suspi-
cious microcalcification seen in mammography should be 
verified in a biopsy. 
A study by Catherine S. Giess et al. from 2016 [23] sho-
wed that the main indications for MR mammography should 
be the situations where there is a doubt as to whether the 
X-ray mammographic findings are clinically relevant or in-
deed if any lesions actually exist.
Indications for mammography should therefore be 
asymmetric densities or archtectural distortions visible in 
only one mammographic projection and the lesions requ-
iring a biopsy, when for whatever reason this proves difficult 
or impossible to undertake. 
Yoo et al. [24] demonstrated the usefulness of MR mam-
mography in assessing the features of well-defined breast 
lesions. The vast majority of these are benign lesions such 
as cysts, fibroadenomas or intramammary lymph nodes, but 
similar ultrasound or mammographic appearances may also 
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be produced by cancers and phylloides tumours. This study 
concluded that MR imaging comprising the analysis of T2-
-weighted images, of the morphology and of the contrast 
enhancement kinetics, is useful in differentiating between 
well-defined benign and malignant lesions.
A meta-analysis by Dorrius Mi et al. [25], assessing BI-
RADS 3 (probably benign) breast lesions, concluded that 
MR mammography is useful in the evaluation of BIRADS 3 
lesions; NPV of the MR mammography for assessing BIRAD 
3 lesions without microcalcification was 100%. According 
to the authors, no follow up imaging is needed after the MR 
mammography for the women with X-ray mammography 
— BIRADS 3 lesions without microcalcification. 
An important question is whether MR mammography 
can reduce the number of unnecessary biopsies of benign 
lesions, and thus better characterise the BIRADS 4 lesions 
seen in X-ray mammography and in breast ultrasound.
A study by Strobel et al. on 353 BIRADS 4 breast lesions 
in 340 women found that 92% of the biopsies might have 
been avoided [26]. In order to improve the specificity of the 
study and therefore reduce the number of false-positive 
results, a high temporal resolution acquisition, covering the 
first 60–90 s after i.v. administration of contrast agents, as 
well as diffusion weighted imaging are used. 
A prospective study by Bickelhaupt et al. concluded that 
diffusion-weighted imaging with background suppression 
(DWIBS), performed without an administration of an in-
travenous contrast agent, is helpful in excluding cancer in 
women with suspecious lesions found in screening X-ray 
mammography (sensitivity 92%, specificity 94%, NPV 92%, 
PPV 93%) [27].
Conclusions
1. X-ray mammography supplemented by breast ultra-
sound scan remains the principal modality in the diagnosis 
of breast cancer. 
2. Tomosynthesis (DBT) reduces the number of equivocal 
mammographic findings and improves the sensitivity and 
specificity of mammography.
3. Indications for MR mammography include:
 — screening women with a high risk of developing breast 
cancer;
 — preoperative staging of breast lesions in women with 
known breast cancer;
 — evaluating response to neoadjuvant chemotherapy;
 — occult primary breast cancer (searching for breast cancer 
in patients with metastases and negative X-ray mammo-
graphy and breast ultrasound);
 — suspected local recurrence when needle biopsy proves 
unfeasible;
 — further characterisation of equivocal lesions found in 
X-ray mammography and breast ultrasound;
 — evaluating breast implants; importantly, breast implants 
do not reduce the sensitivity of MR mammography in 
detecting breast cancer.
4. In some instances, contrast-enhanced spectral mam-
mography may be used instead of MR mammography.
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